Exenatide outperforms detemir in A1C reduction

01/11/2013 | DailyRx.com

Data on 216 diabetes patients showed 44.1% of those who took exenatide once a week attained an A1C of 7% or less, compared with only 11.4% in those who had insulin detemir treatment. Researchers also found patients in the exenatide group lost about 6 pounds, compared with a gain of about 1.8 pounds in the detemir group. The results appear in Diabetes Care.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA